A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus
intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The
anticipated time on study treatment is 3-12 months.